Patents by Inventor Klaus Eckart

Klaus Eckart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzophene-linked crf and crf-like peptides for covalent labeling of corticotropin-releasing factor crf binding protein
    Publication number: 20040260071
    Abstract: The present invention relates to a ligand of the Corticotropin-Releasing Factor (CRF)-binding protein (CRFBP) selected from the group consisting of CRF, Urocortin (Ucn), and Urotensin, said ligand comprising a covalently linked benzophenone moiety. Further, the present invention relates to a process for the purification of a CRFBP which comprises reacting said CRFBP with the ligand of the invention, performing photoaffinity labeling, and purifying the resultant photoreaction products by HPLC. The present invention also relates to the use of the ligand of the invention for detecting CRFBP and for identifying the binding site within CRFBP. The present invention also relates to a method for identifying an inhibitor of the binding of ARF to CRFBP.
    Type: Application
    Filed: July 30, 2004
    Publication date: December 23, 2004
    Inventors: Klaus Eckart, Joachim Spiess, Olaf Jahn
  • Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr)
    Publication number: 20040049009
    Abstract: The present invention relates to a method for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (CRFR). Further, the present invention relates to an antagonist of the ligand of the corticotropin-releasing factor receptor (CRFR) comprising or alternatively consisting of the amino acid sequence of astressin wherein at least Ala at position 11 is replaced by another amino acid. Further, the present invention relates to an antibody directed against the agonist or antagonist of the present invention. Also described is an anti-idiotypic antibody which is directed against the antibody(ies) of the invention. The present invention also relates to a pharmaceutical or diagnostic composition comprising the antagonist, the agonist, the antibody(ies) and/or the anti-idiotypic antibody of the invention.
    Type: Application
    Filed: July 21, 2003
    Publication date: March 11, 2004
    Inventors: Klaus Eckart, Joachim Spiess, Olaf Jahn